Cipla USA Inc., Inc., the US subsidiary of Cipla Limited, is the first Indian company to be approved by US FDA in 1985. Through a comprehensive partnership approach model, Cipla has been dedicated to providing access to medicines to US patients for over 30 years.
The company has executed US partnerships and has commercialized products in the US. Cipla has supported the development of more than 170 ANDAs.
Cipla has an active internal pipeline including several key respiratory products and other complex generics. Cipla launched its US label in January 2015. In September 2015, Cipla's UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.
For more information visit us at www.ciplausa.com